Evaluation of the Relationship Between ABCG2 Mutation and Teriflunomide Exposure and Safety in Chinese RMS Patients Treated With Teriflunomide 14 mg Once Daily for 24 Weeks
PHASE4CompletedINTERVENTIONAL
Enrollment
82
Participants
Timeline
Start Date
May 20, 2020
Primary Completion Date
July 12, 2021
Study Completion Date
July 12, 2021
Conditions
Multiple Sclerosis
Interventions
DRUG
TERIFLUNOMIDE
Pharmaceutical form:tablet Route of administration: oral